MeSH tree: E02.774
The U.S. Food and Drug Administration has approved Johnson & Johnson's Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist, for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric ...
Mar 25, 2026
0
4
Since the mass introduction of antibiotics last century, bacteria have been fighting back with an arsenal of defensive mechanisms. Some produce enzymes that can digest the antibiotic molecule before it takes effect. Others ...
Feb 22, 2026
0
11
Some people may experience the "winter blues"—feeling sad from short days, climbing into bed earlier and resenting waking up on dark mornings. That's different than seasonal affective disorder (SAD), a term used to describe ...
Feb 16, 2026
0
6
In northern climates, February has a particular heaviness. Even though we've passed the longest night of year, the days often feel darker, longer and more draining than December ever did. For society's "night owls," whose ...
Feb 10, 2026
0
8
Past research has found that exposure to bright lights and high levels of noise can alter both physiological processes and human behavior. For instance, an elevated or limited exposure to bright lights and noise has been ...
Conventional pancreatic cancer treatments face a critical hurdle due to the dense tumor microenvironment (TME). This biological barrier surrounds the tumor, severely limiting the infiltration of chemotherapy agents and immune ...
Dec 11, 2025
0
10
The Nordic countries are no strangers to the long, dark winter.
Dec 7, 2025
0
19
A wireless, portable incubator that could transform care for premature infants is reported in the International Journal of Medical Engineering and Informatics. It offers remote monitoring and automated environmental control ...
Nov 13, 2025
0
16
Researchers at the Madrid Institute for Advanced Studies in Nanoscience (IMDEA Nanociencia) and the National Center for Biotechnology (CNB-CSIC) have developed an innovative technique to destroy cancer cells by inducing a ...
Nov 4, 2025
0
34
Australian-founded medical technology company SYMBYX today announced compelling results from a 72-week randomized controlled trial (RCT) demonstrating improvements in a range of Parkinson's disease symptoms. These results, ...
Oct 23, 2025
0
22
